The Company’s lead product is Orazom 3907 which is an application of Orazom to Paclitaxel, an effective and widely prescribed off-patent cancer chemotherapeutic agent.  By orally administering Orazom 3907, cancer patients will avoid the highly unpleasant and inconvenient aspects of iv administered Paclitaxel that are also extremely costly to patients and third-party payers.

The Orazom technology is perceived to be applicable both to a wide variety of already FDA-approved therapeutic molecules and to hydrophobic compounds in the development pipelines of drug manufacturers.  Zomanex intends to begin development of  a second orally delivered drug compound in late 2015.